Florida Senate - 2019 CS for SB 630 By the Committee on Health Policy; and Senators Perry and Baxley 588-03681-19 2019630c1 1 A bill to be entitled 2 An act relating to nonopioid alternatives; amending s. 3 456.44, F.S.; providing a legislative finding; 4 requiring the Department of Health to develop and 5 publish on its website an educational pamphlet 6 regarding the use of nonopioid alternatives for the 7 treatment of pain; requiring that the pamphlet include 8 specified information, including the advantages and 9 disadvantages of the use of such alternatives; 10 providing requirements for health care practitioners; 11 providing an exception; providing an effective date. 12 13 Be It Enacted by the Legislature of the State of Florida: 14 15 Section 1. Subsection (7) is added to section 456.44, 16 Florida Statutes, to read: 17 456.44 Controlled substance prescribing.— 18 (7) NONOPIOID ALTERNATIVES.— 19 (a) The Legislature finds that every competent adult has 20 the fundamental right of self-determination regarding decisions 21 pertaining to his or her own health, including the right to 22 refuse an opioid drug listed as a Schedule II controlled 23 substance in s. 893.03 or 21 U.S.C. s. 812. 24 (b) The department shall develop and publish on its website 25 an educational pamphlet regarding the use of nonopioid 26 alternatives for the treatment of pain. The pamphlet must, at a 27 minimum, include: 28 1. Information on available nonopioid alternatives for the 29 treatment of pain, including nonopioid medicinal drugs or drug 30 products and nonpharmacological therapies; and 31 2. The advantages and disadvantages of the use of nonopioid 32 alternatives. 33 (c) Except in the provision of emergency services and care, 34 as defined in s. 395.002, before providing anesthesia or 35 ordering, administering, dispensing, or prescribing an opioid 36 drug listed as a Schedule II controlled substance in s. 893.03 37 or 21 U.S.C. s. 812 for the treatment of pain, a health care 38 practitioner shall: 39 1. Inform the patient of available nonopioid alternatives 40 for the treatment of pain, which may include nonopioid medicinal 41 drugs or drug products, interventional procedures or treatments, 42 acupuncture, chiropractic treatments, massage therapy, physical 43 therapy, occupational therapy, or any other appropriate therapy 44 as determined by the health care practitioner; 45 2. Discuss the advantages and disadvantages of the use of 46 nonopioid alternatives, including whether the patient is at a 47 high risk of, or has a history of, controlled substance abuse or 48 misuse and the patient’s personal preferences; 49 3. Provide the patient with the educational pamphlet 50 described in paragraph (b); and 51 4. Document the nonopioid alternatives considered in the 52 patient’s record. 53 Section 2. This act shall take effect July 1, 2019.